Technical / White Paper
Biomarkers of Toxicity Panel in Clinical Trials
Most drug candidates are discontinued because of induced organ toxicity and half of them owe this to liver toxicity. This issue explains why drug developers need to be aware of the latest options for liver and kidney laboratory safety testing, and understand the importance of testing a combination of novel, early predictive toxicity biomarkers, along with the conventional tests.
